Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017 Jun 5, 2017
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain Jun 1, 2017 Life Science
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone May 30, 2017 Life Science
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success May 23, 2017 Life Science
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results May 19, 2017 Life Science
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial May 15, 2017 Life Science
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) May 12, 2017 Life Science
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) May 9, 2017 Life Science
China’s ‘precision medicine’ initiative gets lift from latest genomics company funding May 2, 2017 Life Science
DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma (“GBM”) at ASCO Annual Meeting Apr 28, 2017 Life Science
DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme Apr 26, 2017 Life Science
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D Apr 24, 2017 Life Science
DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 22, 2017 Life Science
RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® Apr 18, 2017 Life Science
DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 14, 2017 Life Science
